ACSTAcasti Pharma Inc.

Nasdaq acastipharma.com


$ 2.88 $ 0.01 (0.34 %)    

Thursday, 27-Jun-2024 09:49:56 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 2.97
$ 2.88
$ 0.00 x 0
$ 0.00 x 0
$ 2.88 - $ 2.88
$ 1.72 - $ 3.84
8,489
na
27.92M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 06-21-2024 03-31-2024 10-K
2 02-12-2024 12-31-2023 10-Q
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 06-23-2023 03-31-2023 10-K
6 02-14-2023 12-31-2022 10-Q
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 06-21-2022 03-31-2022 10-K
10 02-14-2022 12-31-2021 10-Q
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-22-2021 03-31-2021 10-K
14 02-09-2021 12-31-2020 10-Q
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 06-29-2020 03-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acasti-pharma-q3-eps-021-up-from-052-yoy

Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0...

 craig-hallum-initiates-coverage-on-acasti-pharma-with-buy-rating-announces-price-target-of-6

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces P...

 acasti-announces-poster-detailing-gtx-104-strive-on-trial

The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhag...

 why-keycorp-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...

 acasti-pharma-inc-files-for-shelf-of-up-to-66m-common-shares-by-selling-stockholders

-SEC Filing

 why-td-synnex-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results...

 why-acasti-pharma-acst-stock-is-exploding-higher

Acasti Pharma Inc (NASDAQ: ACST) shares are trading higher by 34.3% to $2.35 Tuesday morning after the company announced $7.5 m...

 acasti-to-present-gtx-104-pharmacokinetic-comparison-data-at-neurocritical-care-annual-meeting

Acasti Pharma Inc. (NASDAQ:ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104...

 acasti-announces-wuxi-clinical-as-cro-to-conduct-strive-on-phase-3-safety-trial-for-gtx-104-in-asah-patients

STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nim...

 acasti-pharma-announces-1-for-6-reverse-stock-split

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104...

 why-1847-holdings-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from ...

 update-acasti-pharma-q4-adj-eps-011-inline

Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a ...

 recap-acasti-pharma-q4-earnings
Recap: Acasti Pharma Q4 Earnings
06/23/2023 12:20:07

 acasti-pharma-q4-adj-eps-011-inline-cash-balance-of-279m

Acasti Pharma (NASDAQ: ACST) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a...